Breaking News Instant updates and real-time market news.

GSK

GlaxoSmithKline

$38.18

-0.275 (-0.72%)

15:53
11/18/16
11/18
15:53
11/18/16
15:53

FDA approves expansion of GSK flu vaccine to include infants 6 months and older

GSK announced it has received approval from the US Food and Drug Administration's Center for Biologics Evaluation and Research expanding the indication for FluLaval Quadrivalent to include use in children 6 months and older. Prior to this, the vaccine was only approved for active immunization against influenza A subtype viruses and type B viruses, in persons 3 years of age and older. "The flu is a serious disease with a significant impact on public health and can lead to thousands of deaths in the US every flu season," said Patrick Desbiens, Senior Vice President, US Vaccines. "Children are particularly at risk from complications associated with flu, and vaccination is the best way parents can help protect them against this serious illness. This expanded indication builds upon GSK's commitment to influenza vaccines and its legacy as the first manufacturer to bring quadrivalent flu vaccines to the US market." Before the approval of an expanded age indication for FluLaval Quadrivalent, providers who preferred prefilled syringes had to order and stock two separate influenza vaccines to be able to immunize all patients. With this approval, providers are now able to use the same dose of FluLaval Quadrivalent to vaccinate all recommended persons aged 6 months and older. Reference Link

  • 29

    Nov

GSK GlaxoSmithKline
$38.18

-0.275 (-0.72%)

09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/16
RBCM
10/03/16
NO CHANGE
Target $95
RBCM
Outperform
Gilead HIV franchise could see risk from competitor data, says RBC Capital
RBC Capital analyst Michael Yee said his conversations with doctors leads him to think two dolutegravir HIV "doublet" studies being conducted by GlaxoSmithKline (GSK) and ViiV Healthcare - Glaxo's joint venture with Pfizer (PFE) and Shionogi - are likely to work and present an underappreciated risk to Gilead's (GILD) HIV franchise. Talks with investors lead Yee to believe few are even aware of this risk and that the consensus view is underestimating the probability these non-inferiority trials will work. Arguing that the consensus view should factor in more conservative assumptions for Gilead's HIV business post 2018 due to this risk, Yee cut his price target on Gilead to $95 from $105, but keeps an Outperform rating on the shares.
10/06/16
PIPR
10/06/16
NO CHANGE
Target $46
PIPR
Overweight
Piper thinks Alnylam failure is positive for Ionis
Piper Jaffay analyst Joshua Schimmer thinks Alnylam Pharmaceuticals' (ALNY) "abrupt halt" of revusiran for TTR cardiomyopathy is likely a positive for Ionis Pharmaceuticals' (IONS) transthyretin program. The move "knocks out a competitive drug" while Ionis and GlaxoSmithKline (GSK) remain on their previously indicated timeline, Schimmer tells investors in a research note. The analyst at this point believes Alnylam's setback will be limited to revusiran and not read-through to other Gal-Nac programs or other TTR cardiomyopathy or polyneuropathy programs. He keeps an Overweight rating on Ionis with a $46 price target,
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.

TODAY'S FREE FLY STORIES

HLX

Helix Energy

$7.41

-0.32 (-4.14%)

19:24
02/20/17
02/20
19:24
02/20/17
19:24
Earnings
Helix Energy reports Q4 EPS with items (46c), may not compare to consensus (6c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

CSII

Cardiovascular Systems

$29.19

0.76 (2.67%)

19:21
02/20/17
02/20
19:21
02/20/17
19:21
Hot Stocks
Cardiovascular Systems reports one-year data from COAST study »

Cardiovascular Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRMT

America's Car-Mart

$38.85

-1.15 (-2.88%)

19:17
02/20/17
02/20
19:17
02/20/17
19:17
Earnings
America's Car-Mart reports Q3 EPS 35c, may not compare to consensus 64c »

Reports Q3 revenue $139M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

ROG

Rogers Corporation

$78.80

-1.34 (-1.67%)

19:12
02/20/17
02/20
19:12
02/20/17
19:12
Earnings
Rogers Corporation sees Q1 adjusted EPS $1.09-$1.19, consensus 99c »

Sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 01

    Mar

ROG

Rogers Corporation

$78.80

-1.34 (-1.67%)

19:11
02/20/17
02/20
19:11
02/20/17
19:11
Earnings
Rogers Corporation reports Q4 EPS 94c, consensus 82c »

Reports Q4 revenue $173M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 01

    Mar

HBHC

Hancock Holding

$46.80

-0.2 (-0.43%)

, FNBC

First NBC Bank

$4.75

-0.25 (-5.00%)

19:04
02/20/17
02/20
19:04
02/20/17
19:04
Hot Stocks
Hancock Holding says gets approval to close First NBC Bank transaction »

Hancock Holding (HBHC)…

HBHC

Hancock Holding

$46.80

-0.2 (-0.43%)

FNBC

First NBC Bank

$4.75

-0.25 (-5.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDSN

Nordson

$119.95

0.77 (0.65%)

19:03
02/20/17
02/20
19:03
02/20/17
19:03
Earnings
Nordson sees Q2 EPS $1.21-$1.33, consensus $1.22 »

Sees Q2 revenue up 3%-7%.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

NDSN

Nordson

$119.95

0.77 (0.65%)

19:01
02/20/17
02/20
19:01
02/20/17
19:01
Hot Stocks
Breaking Hot Stocks news story on Nordson »

Nordson says order rates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

NDSN

Nordson

$119.95

0.77 (0.65%)

19:00
02/20/17
02/20
19:00
02/20/17
19:00
Earnings
Nordson reports Q1 EPS 86c, consensus 82c »

Reports Q1 revenue $407M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

NDSN

Nordson

$119.95

0.77 (0.65%)

18:57
02/20/17
02/20
18:57
02/20/17
18:57
Hot Stocks
Nordson to acquire Vention AT for $705M »

Nordson announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

CYH

Community Health

$6.90

-0.22 (-3.09%)

18:55
02/20/17
02/20
18:55
02/20/17
18:55
Earnings
Community Health sees FY17 cont ops EPS 30c-$1.10 »

EPS consensus 61c. Sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 21

    Mar

CYH

Community Health

$6.90

-0.22 (-3.09%)

18:51
02/20/17
02/20
18:51
02/20/17
18:51
Earnings
Community Health reports Q4 adjusted EPS 46c, may not compare to consensus 13c »

Reports Q4 net operating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 21

    Mar

HSIC

Henry Schein

$168.11

0.86 (0.51%)

18:47
02/20/17
02/20
18:47
02/20/17
18:47
Hot Stocks
Henry Schein to acquire Southern Anesthesia + Surgical »

Henry Schein announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 23

    Feb

  • 24

    Feb

UIHC

United Insurance

$15.95

0.01 (0.06%)

18:45
02/20/17
02/20
18:45
02/20/17
18:45
Earnings
United Insurance reports Q4 EPS (49c), consensus (39c) »

Reports Q4 revenue $131M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 20

    Mar

VIPS

Vipshop

$12.16

-0.13 (-1.06%)

18:40
02/20/17
02/20
18:40
02/20/17
18:40
Earnings
Breaking Earnings news story on Vipshop »

Vipshop sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

VIPS

Vipshop

$12.16

-0.13 (-1.06%)

18:39
02/20/17
02/20
18:39
02/20/17
18:39
Earnings
Vipshop reports Q4 adjusted income per ADS 23c, consensus 21c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

WFC

Wells Fargo

$58.09

-0.03 (-0.05%)

, BK

BNY Mellon

$47.14

0.07 (0.15%)

18:36
02/20/17
02/20
18:36
02/20/17
18:36
Hot Stocks
Wells Fargo names two new independent directors »

The board of Wells Fargo…

WFC

Wells Fargo

$58.09

-0.03 (-0.05%)

BK

BNY Mellon

$47.14

0.07 (0.15%)

SPLS

Staples

$9.31

0.04 (0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

BIOA

BioAmber

$3.66

-0.07 (-1.88%)

18:33
02/20/17
02/20
18:33
02/20/17
18:33
Hot Stocks
BioAmber says CEO Huc resigns, COO Orecchioni appointed president »

BioAmber announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBB

Cincinnati Bell

$19.85

-0.65 (-3.17%)

18:31
02/20/17
02/20
18:31
02/20/17
18:31
Hot Stocks
Cincinnati Bell subsidiary acquires SunTel Services »

CBTS, a wholly-owned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

VZ

Verizon

$49.19

0.73 (1.51%)

, AAPL

Apple

$135.72

0.375 (0.28%)

18:23
02/20/17
02/20
18:23
02/20/17
18:23
Hot Stocks
Verizon appoints Apple's Andrew McKechnie as creative chief of in-house agency »

Verizon (VZ) announced…

VZ

Verizon

$49.19

0.73 (1.51%)

AAPL

Apple

$135.72

0.375 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 13

    Mar

NEE

NextEra Energy

$126.86

0.67 (0.53%)

18:19
02/20/17
02/20
18:19
02/20/17
18:19
Hot Stocks
NextEra Energy subsidiary says expands solar energy projects »

NextEra Energy subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

SNX

SYNNEX

$118.37

-0.23 (-0.19%)

18:14
02/20/17
02/20
18:14
02/20/17
18:14
Hot Stocks
Raritan announces distribution agreement with SYNNEX »

Raritan, a provider of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$14.91

-0.16 (-1.06%)

18:06
02/20/17
02/20
18:06
02/20/17
18:06
Hot Stocks
Freeport McMoRan says fails to reach deal with Indonesia, sees Q1 sales impact »

Freeport McMoRan issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

WEN

Wendy's

$14.13

0.44 (3.21%)

18:01
02/20/17
02/20
18:01
02/20/17
18:01
Hot Stocks
Delight Restaurant Group acquires 30 Wendy's restaurants »

Delight Restaurant Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

CMG

Chipotle

$427.61

2.85 (0.67%)

17:59
02/20/17
02/20
17:59
02/20/17
17:59
Hot Stocks
Chipotle says 'Smarter Pickup Times' technology rolled out across U.S. »

Chipotle announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.